Mechanism of ductal carcinoma in situ to invasive breast cancer

doi:0.3760/cma.j.issn.1673-422X.2018.06.012

Abstract

Abstract: Ductal carcinoma in situ (DCIS) is a precursor of invasive ductal breast cancer, and up to 40% of these lesions will progress to invasive disease if untreated. The microenvironment, genetic aberrations, signal pathways and epigenetics play important roles during the infiltration and transformation of DCIS. Further studies of the infiltration and transformation of DCIS will promote the accurate assessment and prognosis prediction of the patients with DCIS, for finding a comprehensive evaluation standard and the balance between the over and low treatment.

Key words: Breast neoplasms, Carcinoma, intraductal, noninfiltrating, Disease progression

Li Zhiyu, Wu Qi, Sun Shengrong. Mechanism of ductal carcinoma in situ to invasive breast cancer[J]. Journal of International Oncology, 2018, 45(6): 368-370.

References

［1］ Siziopikou KP. Ductal carcinoma in situ of the breast: current concepts and future directions［J］. Arch Pathol Lab Med, 2013, 137(4): 462-466. DOI: 10.5858/arpa.2012-0078-RA. ［2］ Cowell CF, Weigelt B, Sakr RA, et al. Progression from ductal carcinoma in situ to invasive breast cancer: revisited［J］. Mol Oncol, 2013, 7(5): 859-869. DOI: 10.1016/j.molonc.2013.07.005. ［3］ Pandey PR, Saidou J, Watabe K. Role of myoepithelial cells in breast tumor progression［J］. Front Biosci (Landmark Ed), 2010, 15: 226-236. DOI: 10.2741/3617. ［4］ Bombonati A, Sgroi DC. The molecular pathology of breast cancer progression［J］. J Pathol, 2011, 223(2): 307-317. DOI: 10.1002/path.2808. ［5］ Elias EV, de Castro NP, Pineda PH, et al. Epithelial cells captured from ductal carcinoma in situ reveal a gene expression signature associated with progression to invasive breast cancer［J］. Oncotarget, 2016, 7(46): 75672-75684. DOI: 10.18632/oncotarget.12352. ［6］ Rakha EA, Miligy IM, Gorringe KL, et al. Invasion in breast lesions: the role of the epithelialstroma barrier［J］. Histopathology, 2018, 72(7): 1075-1083. DOI: 10.1111/his.13446. ［7］ Ma XJ, Dahiya S, Richardson E, et al. Gene expression profiling of the tumor microenvironment during breast cancer progression［J］. Breast Cancer Res, 2009, 11(1): R7. DOI: 10.1186/bcr2222. ［8］ Witkiewicz AK, Cox DW, Rivadeneira D, et al. The retinoblastoma tumor suppressor pathway modulates the invasiveness of ErbB2positive breast cancer［J］. Oncogene, 2014, 33(30): 3980-3991. DOI: 10.1038/onc.2013.367. ［9］ Malanchi I, SantamariaMartinez A, Susanto E, et al. Interactions between cancer stem cells and their niche govern metastatic colonization［J］. Nature, 2011, 481(7379): 85-89. DOI: 10.1038/nature 10694. ［10］ Espina V, Liotta LA. What is the malignant nature of human ductal carcinoma in situ［J］. Nat Rev Cancer, 2011, 11(1): 68-75. DOI: 10.1038/nrc2950. ［11］ SensAbuázar C, Napolitano E Ferreira E, Osório CA, et al. Downregulation of ANAPC13 and CLTCL1: early events in the progression of preinvasive ductal carcinoma of the breast［J］. Transl Oncol, 2012, 5(2): 113-123. ［12］ Hsu TH, Jiang SY, Chan WL, et al. Involvement of RARRES3 in the regulation of Wnt proteins acylation and signaling activities in human breast cancer cells［J］. Cell Death Differ, 2014, 22(5): 801-814. DOI: 10.1038/cdd.2014.175. ［13］ Benjamin DI, Louie SM, Mulvihill MM, et al. Inositol phosphate recycling regulates glycolytic and lipid metabolism that drives cancer aggressiveness［J］. ACS Chem Biol, 2014, 9(6): 1340-1350. DOI: 10.1021/cb5001907. ［14］ Wang L, Lyu S, Wang S, et al. Loss of FAT1 during the progression from DCIS to IDC and predict poor clinical outcome in breast cancer［J］. Exp Mol Pathol, 2016, 100(1): 177-183. DOI: 10.1016/j.yexmp.2015.12.012. ［15］ Perez AA, Balabram D, Rocha RM, et al. Coexpression of p16, Ki67 and COX2 is associated with basal phenotype in highgrade ductal carcinoma in situ of the breast［J］. J Histochem Cytochem, 2015, 63(6): 408-416. DOI: 10.1369/0022155415576540. ［16］ Sakr RA, Weigelt B, Chandarlapaty S, et al. PI3K pathway activation in HighGrade ductal carcinoma in SituImplications for progression to invasive breast carcinoma［J］. Clin Cancer Res, 2014, 20(9): 2326-2337. DOI: 10.1158/10780432.CCR132267. ［17］ Shi A, Dong J, Hilsenbeck S, et al. The status of STAT3 and STAT5 in human breast atypical ductal hyperplasia［J］. PLoS One, 2015, 10(7): e0132214. DOI: 10.1371/journal.pone.0132214. ［18］ Park SY, Kwon HJ, Lee HE, et al. Promoter CpG island hypermethylation during breast cancer progression［J］. Virchows Arch, 2011, 458(1): 73-84. DOI: 10.1007/s00428-010-1013-6. ［19］ Moelans CB, VerschuurMaes AH, van Diest PJ. Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer［J］. J Pathol, 2011, 225(2): 222-231. DOI: 10.1002/path.2930. ［20］ Hannafon BN, Ding WQ. miRNAs as biomarkers for predicting the progression of ductal carcinoma in situ［J］. AM J Pathol, 2018, 188(3): 542-549. DOI: 10.1016/j.ajpath.2017.11.003. ［21］ Li S, Meng H, Zhou F, et al. MicroRNA132 is frequently downregulated in ductal carcinoma in situ (DCIS) of breast and acts as a tumor suppressor by inhibiting cell proliferation［J］. Pathol Res Pract, 2013, 209(3): 179-183. DOI: 10.1016/j.prp.2012.12.002. ［22］ Farazi TA, Horlings HM, Ten Hoeve JJ, et al. MicroRNA sequence and expression analysis in breast tumors by deep sequencing［J］. Cancer Res, 2011, 71(13): 4443-4453. DOI: 10.1158/0008-5472.CAN-11-0608. ［23］ Galasso M, Costantino G, Pasquali L, et al. Profiling of the predicted circular RNAs in ductal in situ and invasive breast cancer: a pilot study［J］. Int J Genomics, 2016, 2016: 4503840. DOI: 10.1155/2016/4503840.

[1]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[3]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[4]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[5]	Gu Huayan, Zhu Teng, Guo Guilong. Breast microbiota and breast cancer： present and future [J]. Journal of International Oncology, 2024, 51(1): 55-58.
[6]	Wang Jing, Xu Wenting. Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm [J]. Journal of International Oncology, 2023, 50(9): 520-526.
[7]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying. Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients [J]. Journal of International Oncology, 2023, 50(9): 527-531.
[8]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng. Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway [J]. Journal of International Oncology, 2023, 50(8): 449-456.
[9]	Pan Shulan, Liu Chang, He Ping. Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer [J]. Journal of International Oncology, 2023, 50(8): 457-462.
[10]	Wang Wende, Zeng De. Research progress on the mechanism of endocrine therapy resistance for breast cancer [J]. Journal of International Oncology, 2023, 50(6): 352-356.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong. Research progress on targeted therapy of breast cancer with low expression of HER2 [J]. Journal of International Oncology, 2023, 50(4): 236-240.
[13]	Zhou Ting, Xu Shaohua, Mei Lin. Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer [J]. Journal of International Oncology, 2023, 50(3): 144-149.
[14]	Li Lixi, Zhang Di, Luo Yang, Ma Fei. Clinical application of PARP inhibitors in breast cancer [J]. Journal of International Oncology, 2023, 50(2): 91-96.
[15]	Geng Rui, Ma Junqiang, Guo Qiang, Niu Zhaofeng. Tendency of elderly patients with breast cancer to choose comprehensive treatment mode and its influencing factors [J]. Journal of International Oncology, 2023, 50(11): 650-654.